LAKE FOREST, Ill., March 6, 2015 /PRNewswire/ -- Hospira, Inc.
(NYSE: HSP), applauds Sandoz and the U.S. Food and Drug
Administration (FDA) on today's FDA approval of the first
biosimilar in the United States.
This is a watershed moment for improving patient access to safe,
effective and more affordable biologic medicines. As a leading
global provider of biosimilars, Hospira has seen first-hand the
positive impact of biosimilars in other countries, and we are a
proud participant in these early stages of the development of a
pathway for these medicines in the United
States.
Hospira is the only U.S.-based company currently marketing
biosimilars in the highly regulated markets of Europe and Australia, where we have seen biosimilars
decrease the costs of biologics by 20 to 30 percent. This has
allowed European healthcare systems to reduce their healthcare
spending, while at the same time increasing patient access to these
important biologic medicines.
"Biosimilars represent a transformational opportunity to improve
patient access and provide much-needed financial relief to the U.S.
healthcare system," said Sumant Ramachandra, M.D., Ph.D., senior
vice president, Research & Development and Medical &
Regulatory Affairs, and chief scientific officer, Hospira. "This
approval is good news for the entire healthcare system and brings
us one step closer to making these important medications available
for the patients who need them.
"With two biosimilar applications currently under review by the
U.S. FDA, Hospira is committed to bringing more affordable biologic
medicines to patients in the United
States. We look forward to continuing to partner with the
FDA on the approval pathway for our biosimilars, so that more and
more patients and healthcare providers have access to the benefits
of biosimilars," continued Ramachandra.
About Hospira
Hospira, Inc. is the world's leading
provider of injectable drugs and infusion technologies, and a
global leader in biosimilars. Through its broad, integrated
portfolio, Hospira is uniquely positioned to Advance Wellness™ by
improving patient and caregiver safety while reducing healthcare
costs. The company is headquartered in Lake Forest, Ill. Learn more at
www.hospira.com. For more information about
biosimilars, please visit www.biosimilarfacts.com
Private Securities Litigation Reform Act of
1995 --
A Caution Concerning Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements generally relate to future events or Hospira's future
financial or operating performance. In some cases, you can identify
forward-looking statements because they contain words such as
"may," "will," "should," "expects," "plans," "anticipates,"
"could," "intends," "target," "projects," "contemplates,"
"believes," "estimates," "predicts," "potential" or "continue" or
the negative of these words or other similar terms or expressions
that concern Hospira's expectations, strategy, plans or intentions.
Forward-looking statements in this press release include, but are
not limited to Hospira's expectations regarding regulatory
approvals, clinical trials and the actions of competitors.
Hospira's expectations and beliefs regarding these matters may not
materialize, and actual results in future periods are subject to
risks and uncertainties that could cause actual results to differ
materially from those projected. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, including, without
limitation, challenges inherent in creating and developing
compounds and product candidates and economic, competitive,
governmental, regulatory, legal, supply and other factors.
Information on these and additional risks affecting Hospira's
business and operating results are more fully discussed in the
section entitled "Risk Factors" in its most recently filed annual
report on Form 10-K. The forward-looking statements in this press
release are based on information available as of the date hereof,
and Hospira disclaims any obligation to update any forward-looking
statements, except as required by law.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hospira-statement-on-fda-approval-of-the-first-biosimilar-in-the-united-states-300046716.html
SOURCE Hospira, Inc.